Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$37.59MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean E. Brynjelsen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 44
- Beta
- 0.90
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 13.54
Financials
Revenue
$37.59M+7417.8%Net Income
$11.58MEBITDA
$12.79MFree Cash Flow
$7.26MEPS (diluted)
$0.35Shares Outstanding (diluted)
32.79M+898.1%Operating Expenses
$12.62MCash & Debt
$26.84MReturn of Capital
$0.00Revenue by Segment (annual)
$79.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $79.95M | $-4.60M | $-0.17 |
| 2024 | $39.01M | $-3.82M | $-0.15 |
| 2023 | $31.64M | $-936.0K | $-0.04 |
| 2022 | $21.25M | $-9.02M | $-0.36 |
| 2021 | $21.83M | $-1.96M | $-0.08 |
| 2020 | $39.0K | $-27.97M | $-1.33 |
| 2019 | $959.0K | $-18.32M | $-1.02 |
| 2018 | $0.00 | $-12.74M | $-1.99 |
| 2017 | $0.00 | $-7.16M | $-0.41 |
Valuation
ETONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-65.12%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·8d ago·Neutral
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the Company has launched IMPAVIDO® (miltefosine) capsules.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
…Participate at 2026 Wells Fargo Healthcare Conference DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.
View source ↗ - Newsfool.com·52d ago·Negative
Why Eton Pharmaceuticals Is Top of the Class Today Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
View source ↗ - Newsseekingalpha.com·52d ago·Negative
…arnings Like These Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Negative
Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
View source ↗ - Newszacks.com·53d ago·Neutral
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.31 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$0.35 vs $0.19beat
- Thu, May 14$0.05 vs $0.10miss
- Thu, Mar 19$0.05 vs $0.12miss
- Thu, Nov 6$-0.07 vs $0.16miss
- Thu, Aug 7$-0.10 vs $-0.01miss
- Tue, May 13$0.07 vs $0.09miss
Estimates and results for ETON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ETON officers and directors.
- Bought
- —
- Sold
- $25.2m
0 trades
23 trades
- Maier Paul Vsold
- Maier Paul Vsold
- Maier Paul Vsold
- Krempa Davidsold
- Brynjelsen Seansold
- Brynjelsen Seansold
- Brynjelsen Seansold
- Brynjelsen Seansold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Thomas Suozzihouse · NY03 · disclosed Dec 1, 2022 (51d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.